🇺🇸 FDA
Pipeline program

NBI-6024

NBI 6024-0101

Phase 1 small_molecule completed

Quick answer

NBI-6024 for Type 1 Diabetes Mellitus is a Phase 1 program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).

Program details

Company
NEUROCRINE BIOSCIENCES INC
Indication
Type 1 Diabetes Mellitus
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials